Imara M&A

Merger of Enliven and Imara Transaction Summary Overview Management & Programs . ● ● Merger with Enliven, a privately held precision oncology company Strong balance sheet of approximately $300 million of cash and cash equivalents expected to provide funding for operations into early 2026 Upon close, company expected to be renamed "Enliven Therapeutics, Inc." trading as Nasdaq: ELVN Supported by the Board of Directors of both companies and is subject to shareholder approval and other customary closing conditions Expected ownership is approximately 84% Enliven (including those purchasing Enliven shares in the private financing), 16% Imara, subject to adjustment based on Imara's net cash at closing Projected $82.3 million net cash and cash equivalents from Imara and an additional $164.5 million of cash from concurrent financing CVR agreement to provide additional consideration to Imara stockholders if milestone payments are received from the previously announced pending sale of tovinontrine (IMR-687) or a potential sale or license involving IMR-261 Merger and concurrent financing expected to close in 1Q 2023 Existing Enliven management to lead the combined company New Board of Directors will include 9 members (8 existing Enliven, 1 existing Imara) Combined company will focus on advancing the development of Enliven programs 4

View entire presentation